(CercleFinance.com) – Eli Lilly will host a webcast on Monday, July 17, 2023 during the Alzheimer’s Association International Conference.
Keynote addresses will focus on the results of the donanemab TRAILBLAZER-ALZ 2 clinical trial, as well as broader Alzheimer’s disease news.
Eli Lilly announced in early May the positive results of the phase 3 TRAILBLAZER-ALZ 2 study, showing that its donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease.
The trial met the primary endpoint and all secondary endpoints measuring cognitive and functional decline. ‘47% of participants on donanemab showed no decline (compared to 29% of participants on placebo),’ Eli Lilly said.
Based on these results, the pharma company will proceed with global regulatory submissions as quickly as possible and plans to submit an application to the US FDA this quarter.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
